Robuta

https://www.fool.com/investing/2021/01/22/exelixis-gets-fda-approval-for-cabometyx-in-combin/
The regulator's nod represents an important expansion for the drug.
fda approvalin combinationexelixisgetscabometyx
https://www.biospace.com/exelixis-inc-will-webcast-its-june-2-investor-and-analyst-briefing-at-american-society-of-clinical-oncology
exelixis incwebcastjuneinvestoranalyst
https://www.biospace.com/exelixis-inc-reports-xl647-clinical-data-at-b-aacr-nci-eortc-conference-b-updated
exelixis increportsclinicaldataaacr
https://www.biospace.com/press-releases/exelixis-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-on-january-13-2025
j p morganexelixispresentannual
https://www.exelixismedicalaffairs.com/
Learn about Exelixis Medical Affairs and how we improve patient outcomes in our clinical trials through innovation, communication, and research.
medical affairsexelixisinc
https://www.exelixisconstructions.com/en/about-us
exelixisus
https://www.annualreports.com/Company/exelixis-inc
exelixis inccom
https://www.biospace.com/data-from-phase-i-trial-of-exelixis-inc-xl999-establishing-mtd-presented-at-cancer-conference
phase i trialexelixis incdataestablishing